Amneal Pharmaceuticals, Inc. Class A Common Stock AMRX

Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

• Zacks Investment Research 17 sept

  Amneal (AMRX) Surges 8.6%: Is This an Indication of Further Gains?

  Amneal Pharmaceuticals shares surged 8.6% following completion of its Kashiv BioSciences acquisition, creating an integrated biosimilars platform. However, consensus EPS estimates were revised 23.1% lower over the past month, which could limit future gains. Ionis Pharmaceuticals declined 5.1% with unchanged negative EPS expectations.

  

• Zacks Investment Research 27 ago

  5 Defensive Stocks to Buy as Consumer Confidence Hits 7-Month Low

  With consumer confidence hitting its lowest level since January due to inflation concerns and labor market uncertainty, five defensive stocks from consumer staples, healthcare, and utilities sectors are recommended: COCO, DAR, CNC, EXC, and AMRX. These stocks offer upside potential with strong earnings growth estimates and improved analyst consensus over the past 60 days.

  

• GlobeNewswire Inc. 17 jul

  Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations

  Amneal Pharmaceuticals received FDA approval for additional strengths and vial presentations of iohexol injection (350 mg iodine/mL and 300 mg iodine/mL), with planned Q3 2026 launch. The expanded portfolio is expected to address the majority of U.S. iohexol injection market demand, which generated approximately $706 million in annual sales as of May 2026.